Interestingly, they showed that NSUN5-silenced glioma cells are far more sensitive to drugs targeting NQO1 than cell lines where NSUN5 is expressed, and this was reflected also in vivo, where specific anti-NQO1 drugs could increase the survival of mice orthotopically injected with NSUN5-deficient glioma cells, but did not influence the fate of animals injected with NSUN5 proficient cells. Here, NSUN5 is linked to central nervous system cancer.